APA

Meidhof S., Brabletz S., Lehmann W., Preca B., Mock K., Ruh M., Schüler J., Berthold M., Weber A., Burk U., Lübbert M., Puhr M., Culig Z., Wellner U., Keck T., Bronsert P., Küsters S., Hopt U. T., Stemmler M. P. & Brabletz T. (20160225). ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. : EMBO molecular medicine.

Chicago

Meidhof Simone, Brabletz Simone, Lehmann Waltraut, Preca Bogdan-Tiberius, Mock Kerstin, Ruh Manuel, Schüler Julia, Berthold Maria, Weber Anika, Burk Ulrike, Lübbert Michael, Puhr Martin, Culig Zoran, Wellner Ulrich, Keck Tobias, Bronsert Peter, Küsters Simon, Hopt Ulrich T, Stemmler Marc P and Brabletz Thomas. 20160225. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. : EMBO molecular medicine.

Harvard

Meidhof S., Brabletz S., Lehmann W., Preca B., Mock K., Ruh M., Schüler J., Berthold M., Weber A., Burk U., Lübbert M., Puhr M., Culig Z., Wellner U., Keck T., Bronsert P., Küsters S., Hopt U. T., Stemmler M. P. and Brabletz T. (20160225). ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. : EMBO molecular medicine.

MLA

Meidhof Simone, Brabletz Simone, Lehmann Waltraut, Preca Bogdan-Tiberius, Mock Kerstin, Ruh Manuel, Schüler Julia, Berthold Maria, Weber Anika, Burk Ulrike, Lübbert Michael, Puhr Martin, Culig Zoran, Wellner Ulrich, Keck Tobias, Bronsert Peter, Küsters Simon, Hopt Ulrich T, Stemmler Marc P and Brabletz Thomas. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. : EMBO molecular medicine. 20160225.